Treatment of community-acquired pneumonia. Issue 9 (September 2015)

• Record Type: Journal Article
• Authors: Lee, Young R; Houngue, Coovi; Hall, Ronald G
• Is Part Of: Expert review of anti-infective therapy. Volume 13:Issue 9(2015)
• Page Start: 1109
• Page End: 1121
• Publication Date: 2015-09
• Subjects: Anti-infective agents -- Research -- Periodicals; 616.90461
• Languages: English
• ISSNs: 1478-7210

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Community-acquired pneumonia is the sixth leading cause of death in the USA. Adherence to the 2007 Infectious Diseases Society of America/American Thoracic Society community-acquired pneumonia guidelines has been associated with improved clinical outcomes. However, choice between guideline-recommended treatments is at the discretion of the prescribing clinician. This review is intended to discuss the characteristics of these treatment options including dosing frequency, dose adjustment for renal/hepatic dysfunction, serious/common adverse events, drug interactions, lung penetration, pharmacokinetic-pharmacodynamic target and effect of obesity to help guide antimicrobial selection. An increasing portion of patients are receiving expanded empiric coverage for methicillin-resistant <italic>Staphylococcus aureus</italic> as recommended by the American Thoracic Society and Infectious Diseases Society of America for healthcare-associated pneumonia. However, this expanded coverage may not be achieving the desired improvements in clinical outcomes. We expect this increasingly diverse spectrum of patients with pneumonia to eventually result in the merger of these two guidelines to include all patients with pneumonia.</p> </abstract>